Cissus: Dose, Formulations and Safety

Cissus quadrangularis comes out of the trials looking well tolerated. That deserves saying plainly and first, because the temptation on a safety page is to manufacture hazards to look responsible, and that is its own kind of inaccuracy. The reported adverse effects are mild and mostly gastrointestinal, no distinctive organ toxicity has emerged, and nothing in the published record suggests this is a dangerous plant.

What it is is an unstandardised, undosed supplement with one interaction that genuinely matters — the reported blood-glucose effect, in people taking diabetes medication — taken mostly by people who take it inside a stack of six other things, which makes attributing anything to it very hard. The useful safety work on this page is therefore less about toxicity than about what nobody knows, and about why two bottles both labelled "Cissus extract" may not be the same product at all.

Table of Contents

1. There Is No Established Dose
2. Forms, and Why They Are Not Interchangeable
3. Standardisation, and Why a Percentage Means Little
4. Species Identity and What an Assay Cannot Tell You
5. What the Trials Actually Reported
6. The Interaction That Matters
7. Steroidal Constituents: Bone and Hormone Considerations
8. Oxalate, Kidney Stones and the Fresh Stem
9. Pregnancy, Breastfeeding and Children
10. The Stack Problem
11. Around Surgery
12. Hazards Cissus Does Not Appear to Have
13. What Is Not Known, as a Numbered List
14. Figures This Page Refuses to Give
15. Key Research Papers
16. Connections

There Is No Established Dose

That is the honest headline, and everything below describes what has been used rather than what is recommended.

• The weight-loss trials administered a proprietary standardised extract at a daily amount in the low hundreds of milligrams, split and taken before meals, over roughly eight to ten weeks. That is a description of one research programme's protocol, not a dose established for any person or condition — and the exact figures should be read from the papers rather than from a page like this one.
• Traditional Ayurvedic practice cites dried stem powder in grams per day, and fresh stem juice by the tablespoon. These come from traditional texts and practitioner convention, not from dose-finding studies.
• For fracture healing, joints or tendons — the indications the plant is most famous for — no dose-finding study exists at all. Not a low-quality one; none.
• Duration is unstudied beyond ten weeks. Nobody has examined continuous use over months or years, which is how supplements are actually taken.

The consequence people miss: because extract concentrations differ between products by a large and undisclosed factor, milligram numbers are not comparable across labels. A gram of dried stem powder and a gram of a concentrated extract are entirely different doses of whatever the active material is. Comparing the two as though the number meant the same thing is the commonest dosing error with this plant.

Forms, and Why They Are Not Interchangeable

Five forms circulate, and evidence for one does not transfer to another. This is worth being pedantic about, because most of the confident claims made for Cissus quietly swap forms mid-argument.

• Fresh stem, as a vegetable. The South Indian and Southeast Asian food form — pirandai — requiring the traditional oil-on-hands, scrape-the-ridges handling. Delivers vitamin C, carotenoids, fibre and calcium, plus oxalate. The only form that carries meaningful vitamin C, which matters because the collagen mechanism most often invoked for tendon and bone healing depends on it.
• Dried stem powder. The traditional Ayurvedic and Thai medicinal form, taken by the gram in water, in ghee, or capsuled. Closest to what the historical fracture literature actually studied.
• Standardised extract capsules. The dominant Western form, concentrated and labelled with a percentage of "ketosterones". Essentially no vitamin C survives concentration to a sterol fraction.
• Named proprietary extracts. Trade-named materials are the specific preparations used in the weight-loss trials. If you are trying to match a study, the trade name matters more than the milligram figure — a generic extract has not been studied at all.
• Topical paste. Crushed fresh stem applied over an injury, as the bone-setters did. No controlled human evidence, and the calcium oxalate raphides can irritate broken or sensitive skin. Note that a topical tradition does not support an oral capsule.

Solvent matters too. Much of the cell-culture bone work used a petroleum-ether extract, which pulls the lipophilic sterol and triterpene fraction. A hot-water infusion, an ethanol tincture and a petroleum-ether extract of the same stem are three different chemical mixtures, and a result obtained with one is not evidence for another.

Standardisation, and Why a Percentage Means Little

Cissus extracts are typically sold standardised to a stated percentage of "ketosterones" — commonly figures like 2.5 or 5 percent. Three problems sit inside that number.

1. The assay is not standardised between laboratories. There is no universally agreed analytical method for the fraction, so two products printing the same percentage may not contain comparable amounts of comparable compounds. The number is not a lie so much as not a measurement in the sense a reader assumes.
2. The fraction's pharmacology is not established. Anabolic and cortisol-modulating effects are attributed to it in marketing. What is documented is that the plant contains phytosterols; the mechanism is a hypothesis with a trade name.
3. Higher is not better-studied. Shelf products often carry doses well above what the trials used, because a bigger number sells. There is no dose-response data to support scaling up, and with a plant carrying appreciable oxalate there is a reason not to.

Species Identity and What an Assay Cannot Tell You

The genus Cissus contains several hundred species, and a label reading only "Cissus extract" has not told you what is in the bottle. Only Cissus quadrangularis has the bone-healing tradition and the clinical literature; C. rotundifolia, C. verticillata and others appear in traditional medicine and occasionally in commerce.

A related point that catches people out: a marker-compound assay is a potency check, not an identity check. Standardising to a constituent tells you how much of that constituent is present, not which plant it came from — and where two candidate species share the marker, a certificate of analysis says nothing about identity. Establishing which plant is in a powder requires DNA-based methods, not a percentage on a label. Work such as Newmaster and colleagues' study of contamination and substitution in North American herbal products, in BMC Medicine (2013), is the general backdrop here: substitution in the botanical supply chain is documented and common.

There is also a name hazard worth repeating from the main Cissus page: "devil's backbone" is used for at least three unrelated plants, including Euphorbia tithymaloides, whose caustic white latex burns skin and eyes, and Kalanchoe daigremontiana, which contains cardiac-glycoside-like bufadienolides. Cissus has square, jointed, non-milky green stems and grape-family tendrils, and does not bleed white latex when cut. If a vendor or a seed packet says only "devil's backbone", do not assume it is this plant.

What the Trials Actually Reported

Reported adverse effects across the published human studies were mild, and it would be dishonest to inflate them. The recurring items are:

• Gastrointestinal effects — flatulence, loose stools, abdominal discomfort. The most consistently reported category.
• Headache.
• Dry mouth.
• Occasional insomnia, which is worth reading sceptically given how often Cissus is taken with caffeine.
• Mouth, throat and skin irritation from raw or under-prepared fresh stem. This is the oxalate raphides doing mechanical damage, is expected rather than allergic, and is why the traditional preparation involves oiling the hands and scraping the ridges.

Two caveats belong with that list. The trials were small and short, so they could not detect an adverse event occurring in one user in several hundred, nor anything with a latency longer than ten weeks. And a subchronic toxicity and genotoxicity assessment of a standardised extract has been published in the toxicology literature, which is more than many botanicals have — but it is industry-associated and it is an animal study, so it constrains the plausible hazard rather than clearing the product.

The Interaction That Matters

If you read one section here, read this one. Multiple trials and animal studies report lower fasting blood glucose with Cissus. As a benefit claim that is modest and unconfirmed. As a safety observation it is the single most actionable finding about the plant — the same property described twice, once as an effect and once as a risk.

The additive drugs are the obvious ones: metformin, sulfonylureas (glipizide, glyburide, glimepiride), meglitinides, and insulin, with GLP-1 agonists and SGLT2 inhibitors reasonably included on caution grounds. The realistic failure mode is not a dramatic event on day one. It is a slow drift into more frequent hypoglycaemia in someone whose medication was titrated before they started the supplement — and the symptoms of a low, shakiness, sweating and confusion, are easily misread as a side effect of the herb rather than as an interaction with the prescription.

What to do about it is unglamorous and effective: tell the prescriber before starting, monitor glucose more closely for the first few weeks, know your own hypoglycaemia symptoms, and do not start it in the same week as a medication change, so that if something shifts you know which variable moved. See Diabetes and Hemoglobin A1C.

A note on the phrase "no known interactions", which appears on Cissus labels and in supplement databases. It does not mean interactions have been looked for and not found. It means no interaction study exists — and for a plant with a documented glucose signal, taken by a population that is disproportionately medicated, absent data is not reassurance.

Steroidal Constituents: Bone and Hormone Considerations

The plant contains phytosterols, and the industry markets a ketosteroid fraction. Two theoretical considerations follow. Both are labelled theoretical deliberately: neither is a documented interaction, and inventing one would be as inaccurate as ignoring it.

• Additive effects with other agents acting on bone. Anyone taking a prescription osteoporosis therapy, or high-dose vitamin D and calcium under supervision, is already on a regimen with monitored targets. Adding an unquantified botanical with claimed osteogenic activity does not obviously help and does make the picture harder to read.
• Hormonal uncertainty. Because the marketed fraction is steroidal in structure, additive effects with hormone therapies, aromatase inhibitors or hormonal contraception cannot be excluded — and cannot be quantified, because no adequate human endocrine study of oral Cissus exists. Anyone on hormone-sensitive treatment, or being treated for a hormone-sensitive cancer, should treat that uncertainty as a reason to ask rather than to assume.

The wider point: structural resemblance to a hormone is not pharmacology, and this page does not claim the plant is hormonally active. It claims nobody has established that it is not.

Oxalate, Kidney Stones and the Fresh Stem

The fresh stem contains calcium oxalate raphides — needle-shaped crystals that cause the itching and mouth-burning of raw pirandai. Three practical consequences:

• Anyone with a history of calcium-oxalate kidney stones should avoid the vegetable, and be cautious with powders made from whole dried stem. See Kidney Stones.
• People with chronic kidney disease handle oxalate poorly; avoidance is the conservative position.
• Calcium supplements and Cissus taken together reduce each other's absorption, since oxalate binds calcium in the gut. Separating them by a couple of hours is the sensible handling. Note that this is also why the plant's high paper calcium content does not make it a calcium supplement — much of the calcium is locked in the crystals. See Calcium.

The traditional cooking method is a genuine mitigation rather than folklore: oiling the hands, scraping the four ridges and the nodes, cooking the stem thoroughly, and eating it as a small condiment rather than a bulk vegetable. Concentrated extracts are a different matter — how much oxalate survives into a given commercial extract depends on the process and is generally not disclosed.

Pregnancy, Breastfeeding and Children

There is no adequate human safety data in pregnancy or breastfeeding, and none in children. The traditional literature does not fill that gap; it records use, not safety monitoring.

It is worth stating what the plant's names do not imply here. Unlike herbs whose folk names encode an action on the uterus — and therefore a reason for caution in pregnancy — hadjod and asthisamharaka refer only to bone. That check comes back clear, which means the pregnancy position rests on absent data rather than on a mechanistic red flag. Absent data is still a reason to avoid it: the asymmetry between an unproven benefit and an unquantified fetal risk does not favour taking it.

The Stack Problem

Cissus is overwhelmingly taken inside a stack, and that shapes both safety assessment and any judgement of benefit.

Products combine it with Irvingia gabonensis, green tea extract, caffeine, chromium, garcinia, glucosamine, chondroitin, MSM, collagen, boswellia and turmeric. A user on a joint formula plus a pre-workout may be taking eight or more actives simultaneously. Three consequences:

1. Adverse effects get misattributed. Jitteriness, palpitations, insomnia and elevated blood pressure on a stack containing caffeine are caffeine effects. They are frequently recorded as Cissus side effects, which corrupts the safety record in the direction of overstatement.
2. Benefits get misattributed too. If joints feel better on a formula containing boswellia and turmeric, those two have far more human trial data than Cissus and are the likelier explanation.
3. Interaction assessment becomes guesswork. A product combining Cissus with chromium or another glucose-active ingredient stacks two hypoglycaemic signals, and no study has examined that combination.

Practical rule: if you want to know what this plant does to you, use a single-ingredient product and change nothing else at the same time. That is also the version the market least wants to sell.

Around Surgery

The conservative and standard approach to any supplement of this kind is to stop it about two weeks before a scheduled procedure, and to disclose it to the anaesthetist and surgeon regardless. For Cissus the specific reasons are the reported glucose effects, which matter during fasting and perioperative insulin management, and the fact that platelet effects have not been characterised either way. The general reason is that perioperative herbal use is a recognised risk area — the classic reference being Ang-Lee, Moss and Yuan in JAMA (2001) — and an undisclosed supplement is a variable nobody can interpret if something goes wrong.

For someone taking it after a fracture, the same disclosure logic applies to the orthopaedic team. See Cissus for Bone and Fracture Healing.

Hazards Cissus Does Not Appear to Have

Naming what a herb is not guilty of is as much a part of accuracy as naming what it is, and a reader arriving from other herb pages may reasonably wonder about these. On the published record:

• No pyrrolizidine alkaloid problem. Cissus is a Vitaceae, not a Boraginaceae or Asteraceae; the hepatotoxic PA issue that dogs comfrey, coltsfoot and borage does not apply.
• No documented hepatotoxicity signal. No pattern of liver injury reports has emerged for this plant, and this page will not invent a duration cap on the model of herbs that do have one.
• No thiaminase activity of the kind that gives horsetail a duration limit.
• No stimulant-laxative anthranoid content. The gastrointestinal effects reported are mild and not of that mechanism.
• No established anticoagulant mechanism. The plant contains stilbenes, not dicoumarol; a "contains plant phenolics, therefore thins blood" argument is not a mechanism. Where perioperative caution is advised above, it rests on unquantified dose and asymmetric downside, not on a bleeding mechanism.
• No caustic latex. That belongs to Euphorbia tithymaloides, which shares the common name "devil's backbone" and is a different plant entirely.

None of this means the plant is proven safe. It means these specific hazards are absent from the record, and asserting them would be manufacturing risk.

What Is Not Known, as a Numbered List

Absence of data is a finding, so here it is stated as results rather than left for the reader to infer.

1. No human pharmacokinetics. Absorption, plasma concentration, half-life and tissue distribution of the relevant constituents are unstudied, so no in-vitro concentration can be translated into a dose.
2. No dose-finding study for any indication.
3. No chronic-use safety data beyond roughly ten weeks.
4. No drug-interaction study of any kind, including with the diabetes medications where a mechanistic signal exists.
5. No pregnancy, lactation or paediatric data.
6. No standardised analytical method for the marketed ketosterone fraction, so product-to-product comparison is not possible.
7. No published oxalate content for commercial extracts, so the stone-forming risk of a capsule cannot be estimated from the risk of the vegetable.
8. No hepatic or renal safety monitoring data from long-term users.
9. No study of any commonly sold combination — Cissus with Irvingia, caffeine, chromium or glucosamine.

Figures This Page Refuses to Give

• A recommended milligram dose, for any indication. What exists is a description of trial protocols and traditional convention; neither is a recommendation, and the two are not on a common scale.
• A maximum safe dose or duration. No study supports a number, and inventing a cap to look cautious would misrepresent the evidence as much as omitting one.
• An oxalate figure per capsule or per gram. Published plant analyses vary widely with maturity, region and drying; extract processing is undisclosed. A per-dose figure would be a guess with a decimal point.
• A ketosterone content. Not comparable between laboratories.
• A calcium or vitamin C amount per serving. Derived from per-100-gram plant analyses, these mislead by a large factor when applied to a capsule — and most of the calcium is bound as poorly absorbed oxalate.
• An incidence rate for any adverse effect. The trials are too small and too short to support one.

Key Research Papers

Every citation is a PubMed search built from author names and distinctive title words rather than a numeric identifier, so a link cannot silently resolve to the wrong paper. Confirm the record before relying on it. Where a citation is about a different plant or a general problem rather than about Cissus, that is labelled.

1. Safety and efficacy appraisal across the literature. Sawangjit R, Puttarak P, Saokaew S, Chaiyakunapruk N. Efficacy and safety of Cissus quadrangularis L. in clinical use: a systematic review and meta-analysis of randomised controlled trials. Phytotherapy Research, 2017. The best single source for what the trials reported as adverse effects. Find on PubMed.
2. Narrative safety review — read the disclosures. Stohs SJ, Ray SD. A review and evaluation of the efficacy and safety of Cissus quadrangularis extracts. Phytotherapy Research, 2013. Industry-adjacent; a useful compilation whose competing-interests statement should be read alongside its conclusions. Find on PubMed.
3. Subchronic toxicity and genotoxicity of a standardised extract, published in the toxicology literature around 2011. An animal study, industry-associated; confirm metadata from the record. Search PubMed.
4. The trials whose tolerability data this page reports. Oben JE and colleagues, weight-loss and metabolic studies of Cissus-containing materials in Lipids in Health and Disease, 2006 to 2008. Note that several administered a formulation rather than the single plant. Find on PubMed.
5. A comparator-controlled clinical trial in a different indication. Panpimanmas S and colleagues, comparative study of Cissus quadrangularis against a flavonoid venotonic drug and placebo in acute haemorrhoids, Journal of the Medical Association of Thailand, 2010. Useful here mainly for its tolerability reporting against an active comparator. Find on PubMed.
6. Glucose-lowering signal — animal work. Rodent studies reporting antihyperglycaemic and antihyperlipidaemic effects of Cissus quadrangularis extracts. The mechanistic basis of the diabetes-medication caution. Search PubMed.
7. Oxalate and raphides in the stem. Analyses of calcium oxalate content in Cissus quadrangularis and the effect of traditional preparation. Search PubMed.
8. General problem, not Cissus-specific: dietary oxalate and stone risk. The literature on oxalate intake and calcium-oxalate stone formation, which is why the caution above exists. Search PubMed.
9. General problem, not Cissus-specific: botanical substitution. Newmaster SG and colleagues. DNA barcoding detects contamination and substitution in North American herbal products. BMC Medicine, 2013. Why a marker assay is not an identity check. Find on PubMed.
10. General problem, not Cissus-specific: perioperative herbal use. Ang-Lee MK, Moss J, Yuan CS. Herbal medicines and perioperative care. JAMA, 2001. The standard reference for the stop-two-weeks-before convention. Find on PubMed.
11. Constituent chemistry, for anyone assessing the sterol claims. Adesanya SA and colleagues. Stilbene derivatives from Cissus quadrangularis. Journal of Natural Products, 1999. Find on PubMed.

Live PubMed Searches

1. Cissus quadrangularis safety and adverse effects
2. Cissus quadrangularis and oxalate content
3. Cissus quadrangularis and blood glucose
4. Cissus quadrangularis pharmacokinetics — note how little returns.
5. Herb-drug interactions with glucose-lowering drugs

External Resources

• NCCIH — herbal safety and evidence grading.
• NIH Office of Dietary Supplements — supplement fact sheets and label literacy.
• LiverTox — the NIH database of drug- and herb-induced liver injury.
• PubMed — the primary literature.

Connections

• All Herbs
• Cissus quadrangularis — botany, names, constituents and culinary handling.
• Cissus for Bone and Fracture Healing — the traditional claim and its evidence.
• Cissus for Joint and Tendon Pain — one pilot study, and a lot of extrapolation.
• Cissus for Weight and Metabolic Outcomes — where the glucose signal comes from.
• Diabetes — the interaction that actually matters.
• Hemoglobin A1C — what to watch if you take it alongside medication.
• Lipid Panel — the lipid changes the trials reported.
• Kidney Stones — the oxalate caution in full.
• Calcium — why oxalate-bound calcium is not a supplement, and why to separate the two.
• Vitamin C — present in the fresh stem, absent from the extract.
• Vitamin D3 — the bone regimen a botanical should not be substituted into.
• Osteoporosis — monitored targets, and why an unquantified addition muddies them.
• Ashwagandha — the other supplement sold on a cortisol story.

Back to Table of Contents